First‐Pass CYP3A‐Mediated Metabolism of Midazolam in the Gut Wall and Liver in Preterm Neonates
暂无分享,去创建一个
J. N. van den Anker | A. Rostami-Hodjegan | S. D. de Wildt | C. Knibbe | E. Krekels | Huixin Yu | J. M. Brussee | M. J. Brill | B. de Roos
[1] Amin Rostami‐Hodjegan,et al. Reverse Translation in PBPK and QSP: Going Backwards in Order to Go Forward With Confidence , 2017, Clinical pharmacology and therapeutics.
[2] R. Upton,et al. Food, gastrointestinal pH, and models of oral drug absorption , 2017, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[3] D. Teitelbaum,et al. Small Bowel Diameter in Short Bowel Syndrome as a Predictive Factor for Achieving Enteral Autonomy. , 2016, The Journal of pediatrics.
[4] A. Rostami-Hodjegan,et al. Considering Age Variation When Coining Drugs as High versus Low Hepatic Extraction Ratio , 2016, Drug Metabolism and Disposition.
[5] M. Danhof,et al. Semiphysiologically based pharmacokinetic model for midazolam and CYP3A mediated metabolite 1‐OH‐midazolam in morbidly obese and weight loss surgery patients , 2015, CPT: pharmacometrics & systems pharmacology.
[6] Jennifer H. Martin,et al. Pharmacokinetics in neonatal prescribing: evidence base, paradigms and the future , 2015, British journal of clinical pharmacology.
[7] C. Tejos,et al. Intrahepatic portal vein blood volume estimated by non-contrast magnetic resonance imaging for the assessment of portal hypertension. , 2015, Magnetic resonance imaging.
[8] M. Halpern,et al. The role of intestinal epithelial barrier function in the development of NEC , 2015, Tissue barriers.
[9] Leon Aarons,et al. Combining the ‘bottom up’ and ‘top down’ approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data , 2015, British journal of clinical pharmacology.
[10] Arik Dahan,et al. A mechanistic approach to understanding oral drug absorption in pediatrics: an overview of fundamentals. , 2014, Drug discovery today.
[11] A. Krause,et al. Visualization and Communication of Pharmacometric Models With Berkeley Madonna , 2014, CPT: pharmacometrics & systems pharmacology.
[12] K. Vakili,et al. Neonatal liver physiology. , 2013, Seminars in pediatric surgery.
[13] P. Neuvonen,et al. A Semiphysiological Population Pharmacokinetic Model for Dynamic Inhibition of Liver and Gut Wall Cytochrome P450 3A by Voriconazole , 2013, Clinical Pharmacokinetics.
[14] M. Danhof,et al. Developmental Changes in the Expression and Function of Cytochrome P450 3A Isoforms: Evidence from In Vitro and In Vivo Investigations , 2013, Clinical Pharmacokinetics.
[15] J. Barrett,et al. A Workflow Example of PBPK Modeling to Support Pediatric Research and Development: Case Study with Lorazepam , 2013, The AAPS Journal.
[16] N. Roy,et al. The Role of Intestinal Barrier Function in Early Life in the Development of Colitis , 2012 .
[17] S. Wildt. Profound changes in drug metabolism enzymes and possible effects on drug therapy in neonates and children , 2011 .
[18] Patricia J. Johnson. Neonatal Pharmacology—Pharmacokinetics , 2011, Neonatal Network.
[19] P. Wales,et al. Establishing norms for intestinal length in children. , 2009, Journal of pediatric surgery.
[20] R. Hall,et al. Drugs of choice for sedation and analgesia in the neonatal ICU. , 2009, Clinics in perinatology.
[21] P. McNamara,et al. Protein binding predictions in infants , 2008, AAPS PharmSci.
[22] Maria Pia Saccomani,et al. DAISY: A new software tool to test global identifiability of biological and physiological systems , 2007, Comput. Methods Programs Biomed..
[23] Masoud Jamei,et al. Prediction of intestinal first-pass drug metabolism. , 2007, Current drug metabolism.
[24] M. Jamei,et al. Misuse of the Well-Stirred Model of Hepatic Drug Clearance , 2007, Drug Metabolism and Disposition.
[25] J. N. van den Anker,et al. Determinants of drug metabolism in early neonatal life. , 2007, Current clinical pharmacology.
[26] J. S. Collins,et al. Quantitative standards for fetal and neonatal autopsy. , 2006, American journal of clinical pathology.
[27] Amin Rostami-Hodjegan,et al. Prediction of the Clearance of Eleven Drugs and Associated Variability in Neonates, Infants and Children , 2006, Clinical pharmacokinetics.
[28] H. Cavé,et al. LOCALIZATION AND mRNA EXPRESSION OF CYP3A AND P-GLYCOPROTEIN IN HUMAN DUODENUM AS A FUNCTION OF AGE , 2005, Drug Metabolism and Disposition.
[29] Sven Björkman,et al. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. , 2005, British journal of clinical pharmacology.
[30] É. Jacqz-Aigrain,et al. Pharmacokinetics of midazolam during continuous infusion in critically ill neonates , 2004, European Journal of Clinical Pharmacology.
[31] Amin Rostami-Hodjegan,et al. The effects of dose staggering on metabolic drug-drug interactions. , 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[32] Kiyomi Ito,et al. Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[33] J. Valentin. Basic anatomical and physiological data for use in radiological protection: reference values , 2002, Annals of the ICRP.
[34] W. Hop,et al. Pharmacokinetics and metabolism of oral midazolam in preterm infants. , 2002, British journal of clinical pharmacology.
[35] D. G. McCarver,et al. The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. , 2002, The Journal of pharmacology and experimental therapeutics.
[36] W. Hop,et al. Pharmacokinetics and metabolism of intravenous midazolam in preterm infants , 2001, Clinical pharmacology and therapeutics.
[37] G. Tucker,et al. Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis. , 2001, British journal of clinical pharmacology.
[38] G. Kearns,et al. Impact of developmental pharmacology on pediatric study design: overcoming the challenges. , 2000, The Journal of allergy and clinical immunology.
[39] P. Steer,et al. Population pharmacokinetic modeling in very premature infants receiving midazolam during mechanical ventilation: midazolam neonatal pharmacokinetics. , 1999, Anesthesiology.
[40] GJ Harte,et al. Haemodynamic responses and population pharmacokinetics of midazolam following administration to ventilated, preterm neonates , 1997, Journal of paediatrics and child health.
[41] W. Trager,et al. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. , 1994, The Journal of pharmacology and experimental therapeutics.
[42] S D Hall,et al. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. , 1994, Biochemical pharmacology.
[43] Meindert Danhof,et al. Pharmacokinetic‐pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite α‐hydroxymidazolam in healthy volunteers , 1992, Clinical pharmacology and therapeutics.
[44] L. Weaver,et al. Intestinal permeability in the newborn. , 1984, Archives of disease in childhood.
[45] H. Nau,et al. Decreased serum protein binding of diazepam and its major metabolite in the neonate during the first postnatal week relate to increased free fatty acid levels. , 1984, British journal of clinical pharmacology.
[46] R. Touloukian,et al. Normal intestinal length in preterm infants. , 1983, Journal of pediatric surgery.
[47] A. Tur. [Anemia in children]. , 1970, Voprosy okhrany materinstva i detstva.